Placid Jover

CIK: 0002026165

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (37.5%)

Position reduction

Option Exercises (M)3 (37.5%)

Derivative conversions

Awards (A)2 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

TEVA

TEVA PHARMACEUTICAL INDUSTRIES LTD

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 3, 2026
Exercise(M)
Direct
12.8K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 3, 2026
Sale(S)
Direct
12.8K shares at avg. $34.88$447K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2026
Exercise(M)
Direct
14.2K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2026
Sale(S)
Direct
14.2K shares at avg. $31.67$448K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 4, 2026
Award(A)
Restricted Share Units
Direct
38K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 1, 2025
Sale(S)
Direct
6.1K shares at avg. $15.16$92K
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Aug 1, 2025
Exercise(M)
Direct
12.8K shares-
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Mar 5, 2025
Award(A)
Restricted Share Units
Direct
56.6K shares-

		Type	Shares	Price		Ownership
Aug 3, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	12,827	-	$0	Direct
Aug 3, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	12,827	$34.88	$447,351	Direct
Mar 5, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	14,150	-	$0	Direct
Mar 5, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	14,150	$31.67	$448,108	Direct
Mar 4, 2026	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	37,982	-	-	Direct
Aug 1, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Sale(S)	6,053	$15.16	$91,748	Direct
Aug 1, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Exercise(M)	12,827	-	-	Direct
Mar 5, 2025	TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD	Award(A) Restricted Share Units	56,603	-	-	Direct

1-8 of 8 transactions

About Jover Placid

Jover Placid (SEC CIK 0002026165) files insider reports with the SEC as Officer of TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).

Signal8 holds 5 ownership filings by Jover Placid, all Form 4s, filed between Mar 7, 2025 and Aug 5, 2026. Those filings report 8 transactions, from Mar 5, 2025 to Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Jover Placid's filings is in TEL AVIV.

Recent filings by Jover Placid

Aug 3, 2026: Option exercise of TEVA shares (Form 4, code M).
Aug 3, 2026: Open-market sale of TEVA shares (Form 4, code S).
Mar 5, 2026: Option exercise of TEVA shares (Form 4, code M).
Mar 5, 2026: Open-market sale of TEVA shares (Form 4, code S).
Mar 4, 2026: Grant or award of TEVA derivative securities (Form 4, code A).

Other insiders filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Bergwerk Dov, Interim Cheif Legal Officer
Savage Brian, Interim Chief Legal Officer
MIGNONE ROBERTO, Director
Weiss Amir, Chief Accounting Officer
Satchi-Fainaro Ronit, Director
Lippman Evan, EVP, Business Development

How to read Form 4 transaction codes